Acting On Alpha-galatose-glycoside Bond (e.g., Alpha-galactosidase, Etc.) Patents (Class 435/208)
-
Publication number: 20120295327Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: May 25, 2012Publication date: November 22, 2012Applicant: Biomarin Pharmaceutical Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley, William S. Sly
-
Publication number: 20120276567Abstract: The invention relates to a Talaromyces transformant comprising one or more recombinant gene, capable of producing cellulase in the absence of cellulase inducer in a glucose medium, having a cellulase activity of 2 WSU/ml or more, in 16 times or more diluted supernatant or broth.Type: ApplicationFiled: November 4, 2010Publication date: November 1, 2012Applicant: DSM IP ASSETS B.V.Inventors: Alrik Pieter Los, Brenda Vonk, Marco Alexander Berg Van Den, Robbertus Antonius Damveld, Cornelis Maria Jacobus Sagt, Adrianus Wilhelmus Hermanus Vollebregt, Margot Elisabeth Francoise Schooneveld-Bergmans
-
Publication number: 20120266329Abstract: The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. Polypeptides, including enzymes and antibodies, and nucleic acids of the invention can be used in industrial, experimental, food and feed processing, nutritional and pharmaceutical applications, e.g., for food and feed supplements, colorants, neutraceuticals, cosmetic and pharmaceutical needs.Type: ApplicationFiled: February 20, 2012Publication date: October 18, 2012Applicant: BP Corporation North America Inc.Inventors: Eric J. Mathur, Cathy Chang
-
Publication number: 20120252073Abstract: A method of decomposing stubble, which is crop residue left on the ground, and a composition for treating the stubble are disclosed. The method comprises treating the stubble with the composition comprising a) polysaccharide-degrading enzyme; b) wetting agent; and, optionally, c) water and allowing the treated stubble to remain on the ground and decompose.Type: ApplicationFiled: March 28, 2012Publication date: October 4, 2012Applicant: RHODIA OPERATIONSInventors: Jean-Christophe Castaing, Gary Groves, Ashwin Rao, Thomas E. Ruch
-
Publication number: 20120252093Abstract: Promoter regions associated with the Yarrowia lipolytica esterase/lipase (EL1) gene are disclosed and have been found to be particularly effective for the expression of heterologous genes in yeast. These promoter regions will be useful for driving high-level expression of genes involved in the production of omega-3 and omega-6 fatty acids.Type: ApplicationFiled: March 30, 2012Publication date: October 4, 2012Applicant: E I Du Pont De Nemours and CompanyInventor: Quinn Qun Zhu
-
Publication number: 20120195876Abstract: Biomarkers for diagnosis and differentiation between stages of kidney diseases. Methods of treatments and identification of novel therapies are provided.Type: ApplicationFiled: August 13, 2010Publication date: August 2, 2012Inventor: Jochen Reiser
-
Publication number: 20120171722Abstract: The invention provides a method for producing polypeptide protein products and nucleic acid products having reduced levels of antigenicity in an animal being treated with a biologic product. Somatic cells are isolated from an animal, transformed into pluripotent stem cells, transfected with a nucleic acid(s) of interest, and re-differentiated towards somatic cells known to be high level producers of the desired nucleic acid product. The invention can be used to derive a general cell line to treat populations, racial specific cell lines to treat ethnic groups, or patient specific cell lines to treat individuals. Additionally, the invention provides a method to allow induced pluripotent stem cells to be re-differentiated towards their somatic cell of origin so that the cells can be used to therapeutically treat an animal without resulting teratoma formation.Type: ApplicationFiled: January 3, 2012Publication date: July 5, 2012Applicant: AVM Biotechnology, LLCInventor: Theresa A. Deisher
-
Patent number: 8178337Abstract: Carbohydrate utilization-related and multidrug transporter nucleic acids and polypeptides, and fragments and variants thereof, are disclosed in the current invention. In addition, carbohydrate utilization-related and multidrug transporter fusion proteins, antigenic peptides, and anti-carbohydrate utilization-related and anti-multidrug transporter antibodies are encompassed. The invention also provides vectors containing a nucleic acid of the invention and cells into which the vector has been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.Type: GrantFiled: October 13, 2010Date of Patent: May 15, 2012Assignee: North Carolina State UniversityInventors: Todd R. Klaenhammer, Eric R. Altermann, Rodolphe Barrangou, W. Michael Russell, Tri Duong
-
Patent number: 8124073Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.Type: GrantFiled: January 8, 2008Date of Patent: February 28, 2012Assignee: Genzyme CorporationInventor: James Stefano
-
Publication number: 20120003715Abstract: A method for expressing and industrial scale production of recombinant lysosomal enzymes utilizing insect larva including the steps of infecting an insect larva population of the species Spodoptera littoralis via a recombinant baculovirus liquid suspension which permits the expression of at least one gene coding for a protein of interest, at least one of these genes coding for a lysosomal enzyme expressed in the insect larva, collecting of the previously infected insect larva expressing in a sufficient significant quantity the protein of interest and recovering the protein of interest from the collected insect larva.Type: ApplicationFiled: March 13, 2009Publication date: January 5, 2012Applicant: Bioorganic Research and Services S.L.Inventors: Victor Infante Viñolo, Rosa Maria Osuna Aguilar, Juan Jose Infante Viñolo
-
Publication number: 20110280856Abstract: The invention provides highly purified ?-Gal A, and various methods for purifying it; ?-Gal A preparations with altered charge and methods for making those preparations; ?-Gal A preparations that have an extended circulating half-life in a mammalian host, and methods for making same; and methods and dosages for administering an ?-Gal A preparation to a subject.Type: ApplicationFiled: November 11, 2010Publication date: November 17, 2011Inventors: Richard F Selden, Marianne Borowski, Carol M. Kinoshita, Douglas A. Treco
-
Patent number: 8058047Abstract: The present invention concerns a new ?-galactosidase with transgalactosylating activity isolated from Bifidobacterium bifidum. The ?-galactosidase is capable of converting mellibiose to ?-galactobiose disaccharides which may be incorporated into numerous food products or animal feeds for improving gut health by promoting the growth of bifidobacteria in the gut, and repressing the growth of the pathogenic microflora.Type: GrantFiled: December 19, 2006Date of Patent: November 15, 2011Assignee: Clasado, Inc.Inventors: Georgios Tzortzis, Athanasios K Goulas, Theodoros Goulas
-
Publication number: 20110207676Abstract: Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders.Type: ApplicationFiled: April 27, 2011Publication date: August 25, 2011Inventors: Nico Luc Marc Callewaert, Wouter Vervecken, Karen Jacqueline Marcel De Pourcq, Steven Christian Jozef Geysens, Mouna Guerfal
-
Publication number: 20110171198Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: March 21, 2011Publication date: July 14, 2011Applicants: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH, ALTIF LABORATORIESInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Patent number: 7951552Abstract: This invention relates to novel ?-galactosidases for the enzymatic removal of the immunodominant monosaccharides on blood products and tissues. Specifically this invention provides a novel family of ?3 glycosidases, used for the enzymatic removal of type B antigens from blood group B and AB reactive blood products, and the GaIiIi antigen from non-human animal tissues, thereby converting these to non-immunogenic cells and tissues suitable for transplantation.Type: GrantFiled: October 31, 2006Date of Patent: May 31, 2011Assignee: Velico Medical, Inc.Inventors: Qiyong Peter Liu, Henrik Clausen
-
Patent number: 7935336Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: GrantFiled: November 17, 2006Date of Patent: May 3, 2011Assignees: Tokyo Metropolitan Organization for Medical Research, ALTIF LaboratoriesInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Publication number: 20110086408Abstract: Described are compositions and methods relating to cellulase/hemicellulase enzyme blends for improving the enzymatic hydrolysis of cellulosic and hemicellulosic materials, as commonly found in biomassType: ApplicationFiled: March 20, 2009Publication date: April 14, 2011Applicant: Danisco US Inc.Inventors: Scott D. Power, Robert M. Caldwell, Suzanne E. Lantz, Edmund A. Larenas
-
Publication number: 20110045569Abstract: This invention relates to enzymatic removal of type A and B antigens from blood group A, B, and AB reactive cells in blood products, and thereby converting these to non-A and non-B reactive cells. The invention further relates to using unique ?-N-acetylgalactosaminidases and ?-galactosidases with superior kinetic properties for removing the immunodominant monosaccharides of the blood group A and B antigens and improved performance in enzymatic conversion of red blood cells. The preferred unique ?-N-acetylgalactosaminidases and ?-galactosidases exhibit the following characteristics: (i) exclusive, preferred or no less than 10% substrate specificity for the type A and B branched polysaccharide structures relative to measurable activity with simple mono- and disaccharide structures and aglycon derivatives hereof; (ii) optimal performance at neutral pH with blood group oligosaccharides and in enzymatic conversion of cells; and (iii) a favorable kinetic constant Km with mono- and oligosaccharide substrates.Type: ApplicationFiled: May 28, 2010Publication date: February 24, 2011Inventors: Henrik Clausen, Humberto De La Vega, Cheryl Hill, Qiyong Peter Liu
-
Publication number: 20110002908Abstract: The invention provides methods of treating ?-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human ?-galactosidase A are also included.Type: ApplicationFiled: April 15, 2010Publication date: January 6, 2011Inventors: Douglas A. TRECO, Kenneth LOVEDAY, Marianne BOROWSKI
-
Publication number: 20100291059Abstract: The present invention provides a pharmaceutical composition comprising a protein having ?-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an ?-galactosidase activity through alteration of the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: May 19, 2008Publication date: November 18, 2010Applicants: ALTIF LABORATORIES INC.Inventors: Hitoshi Sakuraba, Youichi Tajima, Ikuo Kawashima, Seiichi Aikawa, Fumiko Aikawa
-
Publication number: 20100273235Abstract: The present invention provides an aqueous composition comprising a protein with enzymatic activity of alpha-galactosidase. The present invention further provides a method of stabilizing an aqueous composition comprising a protein with enzymatic activity of alpha-galactosidase, and a method of preparing a purified aqueous composition comprising the protein with enzymatic activity of alpha-galactosidase.Type: ApplicationFiled: April 19, 2010Publication date: October 28, 2010Inventors: Harald Sobek, Manfred Schmidt, Rainer Mueller, Werner Hoelke, Johann-Peter Thalhofer
-
Patent number: 7812033Abstract: Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8-12-alkyl derivatives of N-alkyl-deoxynojirimycin, isofagomine compounds, and calystegine compoiunds are effective to enhance glucocerebrosidase activity.Type: GrantFiled: September 27, 2006Date of Patent: October 12, 2010Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Jian-Qiang Fan, Satoshi Ishii, Naoki Asano
-
Publication number: 20100196345Abstract: A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.Type: ApplicationFiled: April 30, 2008Publication date: August 5, 2010Applicant: ProtalixInventors: Yoseph Shaaltiel, Gideon Baum, Daniel Bartfeld, Sharon Hashmueli, Ayala Lewkowicz
-
Publication number: 20100166728Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: November 17, 2006Publication date: July 1, 2010Applicants: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH, ALTIF LABORATORIESInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Publication number: 20100137184Abstract: The present invention provides cleaning compositions comprising an isolated alpha-galactosidase enzyme. In some particularly preferred embodiments, the isolated alpha-galactosidase enzyme comprises an amino acid sequence that is related to an alpha-galactosidase from Trichoderma reesei. The present invention also provides methods for using the alpha-galactosidase in cleaning applications.Type: ApplicationFiled: February 26, 2008Publication date: June 3, 2010Inventors: Hugh C. McDonald, Ayrookaran J. Poulose
-
Publication number: 20100011456Abstract: The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. Polypeptides, including enzymes and antibodies, and nucleic acids of the invention can be used in industrial, experimental, food and feed processing, nutritional and pharmaceutical applications, e.g., for food and feed supplements, colorants, neutraceuticals, cosmetic and pharmaceutical needs.Type: ApplicationFiled: March 3, 2006Publication date: January 14, 2010Applicant: Verenium CorporationInventors: Eric J. Mathur, Cathy Chang
-
Patent number: 7622291Abstract: Production of efficiently producing agaro-oligosaccharide; a polypeptide having an agarase activity which is usable in, for example, efficiently extracting a substance such as a nucleic acid from an agarose gel; the amino acid sequence of the polypeptide; a gene encoding the polypeptide; a process for producing the polypeptide; a process for producing agaro-oligosaccharide; and a process for extracting a substance such as a nucleic acid from an agarose gel.Type: GrantFiled: November 30, 2007Date of Patent: November 24, 2009Assignee: Takara Bio Inc.Inventors: Jun Tomono, Hiroaki Sagawa, Ikunoshin Kato
-
Patent number: 7622485Abstract: A method of enhancing the activity of lysosomal ?-Galactosidase A (?-Gal A) in mammalian cells and for treatment of Fabry disease by administration of 1-deoxy-galactonojirimycin and related compounds.Type: GrantFiled: June 14, 2004Date of Patent: November 24, 2009Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Jian-Qiang Fan, Satoshi Ishii
-
Publication number: 20090285933Abstract: The present invention concerns a new ?-galactosidase with transgalactosylating activity isolated from Bifidobacterium bifidum. The ?-galactosidase is capable of converting mellibiose to ?-galactobiose disaccharides which may be incorporated into numerous food products or animal feeds for improving gut health by promoting the growth of bifidobacteria in the gut, and repressing the growth of the pathogenic microflora.Type: ApplicationFiled: December 19, 2006Publication date: November 19, 2009Inventors: Georgios Tzortzis, Athanasios K. Goulas, Theodoros Goulas
-
Publication number: 20090220474Abstract: This invention relates to novel ?-galactosidases for the enzymatic removal of the immunodominant monosaccharides on blood products and tissues. Specifically this invention provides a novel family of ?3 glycosidases, used for the enzymatic removal of type B antigens from blood group B and AB reactive blood products, and the GaIiIi antigen from non-human animal tissues, thereby converting these to non-immunogenic cells and tissues suitable for transplantation.Type: ApplicationFiled: October 31, 2006Publication date: September 3, 2009Inventors: Keith Rosiello, Henrik Clausen
-
Patent number: 7560262Abstract: The present invention provides a method of identifying alkaline-?-galactosidases. Also provided are polynucleotide sequences encoding polypeptides having an alkaline-?-galactosidase activity, oligonucleotides and oligonucleotide analogs derived from the polynucleotide sequences, peptides and peptide analogues, antibodies recognizing same and methods of using same.Type: GrantFiled: November 15, 2004Date of Patent: July 14, 2009Assignee: The State of Israel - Ministry of Agriculture & Rural DevelopmentInventors: Arthur Schaffer, Nir Carmi, Marina Petreikov, David Granot, Yoram Eyal
-
Patent number: 7527947Abstract: The present invention relates to a method for producing a polypeptide comprising using a signal peptide, to nucleic acid constructs comprising a first nucleotide sequence encoding the signal peptide and a second nucleotide sequence encoding a polypeptide which is foreign to the first nucleotide sequence. Furthermore, it also relates to expression vectors and host cells comprising the nuclei acid construct.Type: GrantFiled: June 14, 2005Date of Patent: May 5, 2009Assignee: Novozymes A/SInventors: Tomoko Matsui, Henriette Draborg, Steffen Danielsen
-
Patent number: 7514254Abstract: There are provided novel plant-derived enzymes for hydrolysis of sugars and particularly an alkaline alpha-galactosidase which hydrolyzes a broad spectrum of galactosyl-saccharides such as melibiose, raffinose and stachyose and guar gum, at neutral to alkaline pH conditions.Type: GrantFiled: August 8, 2006Date of Patent: April 7, 2009Assignee: The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterInventors: Arthur A. Schaffer, Gao Zhifang
-
Publication number: 20080280818Abstract: The present invention provides sequon polypeptides with an amino acid sequence including one or more exogenous O-linked glycosylation sequence of the invention. In addition, the present invention provides methods of making polypeptide conjugates as well as methods of using such conjugates and their pharmaceutical compositions. The invention further provides libraries of sequon polypeptides, wherein each member of such library includes at least one exogenous O-linked glycosylation sequence of the invention. Also provided are methods of making and using such libraries.Type: ApplicationFiled: July 23, 2007Publication date: November 13, 2008Applicant: Neose Technologies, Inc.Inventor: Shawn DeFrees
-
Publication number: 20080274155Abstract: The invention provides chimeric cannulae polypeptides and nanotubules and methods for making and using them. In one aspect, the invention provides compositions and methods for the identification, separation or synthesis of proteins or ligands. In one aspect, the invention provides compositions and methods for making and using nanotubules. In one aspect, the invention provides compositions and methods for the selection and purification of chiral compositions from racemic mixtures. In one aspect, the chimeric proteins and polymers (e.g., nanotubules, tubules, bundles, balls, fibers, filaments, sheets, threads, textiles) of the invention comprise a detectable moiety, e.g., a fluorescent protein. In one aspect, the invention provides a flame retardant or heat resistant device comprising a sheeting, a covering, a coating or an adhesive comprising a chimeric protein of the invention.Type: ApplicationFiled: March 24, 2005Publication date: November 6, 2008Applicant: Verenium CorporationInventors: Nelson R. Barton, Eileen O'Donoghue, Ryan Short, Gerhard Frey, David Weiner, Dan E. Robertson, Steven Briggs, Paul Zorner
-
Patent number: 7446098Abstract: This application provides methods of improving gene therapy by combining gene therapy with active site-specific chaperones (ASSCs). The ASSC increases the stability and efficiency of the protein encoded by the recombinant gene that is administered.Type: GrantFiled: February 17, 2004Date of Patent: November 4, 2008Assignee: Mount Sinai School of Medicine of New York UniversityInventor: Jian-Qiang Fan
-
Patent number: 7341720Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.Type: GrantFiled: April 5, 2006Date of Patent: March 11, 2008Assignee: Genzyme CorporationInventor: James Stefano
-
Patent number: 7329524Abstract: Production of efficiently producing agaro-oligosaccharide; a polypeptide having an agarase activity which is usable in, for example, efficiently extracting a substance such as a nucleic acid from an agarose gel; the amino acid sequence of the polypeptide; a gene encoding the polypeptide; a process for producing the polypeptide; a process for producing agaro-oligosaccharide; and a process for extracting a substance such as a nucleic acid from an agarose gel.Type: GrantFiled: February 26, 2002Date of Patent: February 12, 2008Assignee: Takara Bio Inc.Inventors: Jun Tomono, Hiroaki Sagawa, Ikunoshin Kato
-
Publication number: 20080014188Abstract: This invention provides compositions of highly phosphorylated lysosomal enzymes, their pharmaceutical compositions, methods of producing and purifying such compounds and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases.Type: ApplicationFiled: February 7, 2005Publication date: January 17, 2008Inventors: Todd C. Zankel, Christopher M. Starr
-
Patent number: 7238858Abstract: The present invention relates to the modification of galactomannans present in the green coffee bean by reducing the endogenous level of ?-D-galactosidase activity. In particular, the present invention pertains to a plant cell with reduced ?-D-galactosidase activity and to a plant harboring such a plant cell.Type: GrantFiled: March 19, 2004Date of Patent: July 3, 2007Assignee: Nestec S.A.Inventors: Pierre Marraccini, Alain François Paul Edmond Deshayes, William John Rogers
-
Patent number: 7141582Abstract: Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8–12-alkyl derivatives of N-alkyl-deoxynojirimycin, isofagomine compounds, and calystegine compounds are effective to enhance glucocerebrosidase activity.Type: GrantFiled: November 16, 2004Date of Patent: November 28, 2006Assignee: Mount Sinai School of New York UniversityInventors: Jian-Qiang Fan, Satoshi Ishii, Naoki Asano
-
Patent number: 7074605Abstract: An isolated and purified ?-N-acetyl-D-galactosaminidase from Clostridium perfringens and homologs thereof are disclosed. A method for purifying and isolating the ?-N-acetylgalactosaminidase from Clostridium perfringens by removing neuramidases is disclosed. A process for using the ?-N-acetylgalactosaminidase from Clostridium perfringens in altering type A blood cells to type O blood cells is disclosed. A process for altering cells expressing blood group A epitope by using ?-N-acetylgalactosaminidase isolated from Clostridium perfringens in altering the cells expressing blood group A epitope to cells expressing blood group O epitope is disclosed.Type: GrantFiled: January 29, 2002Date of Patent: July 11, 2006Assignee: The Curators of the University of MissouriInventor: Daniel S. Smith
-
Patent number: 7056691Abstract: The invention relates to ?-galactosidase and to polynucleotides encoding the ?-galactosidase. In addition methods of designing new ?-galactosidases and method of use thereof are also provided. The ?-galactosidases have increased activity and stability at increased pH and temperature.Type: GrantFiled: April 3, 2002Date of Patent: June 6, 2006Assignee: Diversa CorporationInventors: Jay M. Short, Dennis Murphy, John Reid, Eric J. Mathur
-
Patent number: 7011831Abstract: Fabry disease results from an X-linked deficiency in the enzyme ?-galactosidase A. The present invention is directed to recombinant human ?-galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of ?-galactosidase A are also provided.Type: GrantFiled: September 4, 2002Date of Patent: March 14, 2006Assignee: Research Corporation Technologies, Inc.Inventors: David Hudgins Calhoun, George Coppola
-
Patent number: 7001994Abstract: Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose 6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications.Type: GrantFiled: January 17, 2002Date of Patent: February 21, 2006Assignee: Genzyme CorporationInventor: Yunxiang Zhu
-
Patent number: 6987009Abstract: A thermostable alpha-glycosidase derived from various Thermococcus, alcaliphilus AEDII12RA is disclosed. The enzymes are produced from native or recombinant host cells and can be utilized in the food processing industry.Type: GrantFiled: July 19, 2000Date of Patent: January 17, 2006Assignee: Diversa CorporationInventors: Dennis Murphy, John Reid
-
Patent number: 6987016Abstract: The invention relates to ?-galactosidase and to polynucleotides encoding the ?-galactosidase. In addition methods of designing new ?-galactosidases and method of use thereof are also provided. The ?-galactosidases have increased activity and stability at increased pH and temperature.Type: GrantFiled: June 20, 2001Date of Patent: January 17, 2006Assignee: Diversa CorporationInventors: Dennis Murphy, John Reid, Dan E. Robertson
-
Patent number: 6949369Abstract: The invention relates to ?-galactosidase and to polynucleotides encoding the ?-galactosidase. In addition methods of designing new ?-galactosidases and method of use thereof are also provided. The ?-galactosidases have increased activity and stability at increased pH and temperature.Type: GrantFiled: April 1, 2002Date of Patent: September 27, 2005Assignee: Diversa CorporationInventors: Dennis Murphy, John Reid, Dan E. Robertson
-
Patent number: 6936454Abstract: A method of fracturing a subterranean formation which surrounds a well bore comprises the steps of providing a fracturing fluid, and injecting the fracturing fluid into the well bore at a pressure sufficient to form fractures in the subterranean formation which surrounds the well bore. The pressure is then released from the fracturing fluid, after which the fluid may be removed from the well and the well placed into production. The fracturing fluid comprises an aqueous liquid, a polysaccharide soluble or dispersible in the aqueous liquid in an amount sufficient to increase the viscosity of the aqueous liquid, an enzyme breaker which degrades said polysaccharide at a temperature above 180° F. Fracturing fluid compositions and enzyme breaker systems useful for carrying out the invention are also disclosed.Type: GrantFiled: May 17, 2002Date of Patent: August 30, 2005Assignees: North Carolina State University, The Trustees of Princeton UniversityInventors: Robert M. Kelly, Saad A. Khan, Pascal Leduc, Akash Tayal, Robert K. Prud'homme
-
Patent number: 6916829Abstract: Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8-12-alkyl derivatives of N-alkyl-deoxynojirimycin, isofagomine compounds, and calystegine compoiunds are effective to enhance glucocerebrosidase activity.Type: GrantFiled: November 26, 2002Date of Patent: July 12, 2005Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Jian-Qiang Fan, Satoshi Ishii, Naoki Asano